✦ LIBER ✦

Primary Fallopian Tube Adenocarcinoma in Situ Associated with Adjuvant Tamoxifen Therapy for Breast Carcinoma

✍ Scribed by Heinrich E.M. Sonnendecker; Kumarasen Cooper; Kiran N. Kalian

Book ID: 115616100
Publisher: Elsevier Science
Year: 1994
Tongue: English
Weight: 1004 KB
Volume: 52
Category: Article
ISSN: 0090-8258
DOI: 10.1006/gyno.1994.1069

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Primary fallopian tube adenocarcinoma in

Primary fallopian tube adenocarcinoma in situ associated with adjuvant tamoxifen therapy for breast carcinoma

✍ H.E.M. Sonnendecker; K. Cooper; K.N. Kalian 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 85 KB

Endometrial adenosarcoma with adjuvant t

Endometrial adenosarcoma with adjuvant tamoxifen therapy for primary breast carcinoma

✍ Jagavkar, RS ;Shakespeare, TP ;Stevens, MJ 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 489 KB

Endometrial carcinoma associated with ad

Endometrial carcinoma associated with adjuvant tamoxifen therapy for breast cancer: a French multi-centre analysis of 89 cases

✍ H. Mignotte; J.F. Rodier; A. Lesur; S. Hoffstetter; B. Cutuli; J. D'Anjou; P. Ro 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 608 KB

A genome-wide association study identifi

A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese

✍ Kiyotani, K.; Mushiroda, T.; Tsunoda, T.; Morizono, T.; Hosono, N.; Kubo, M.; Ta 📂 Article 📅 2011 🏛 Oxford University Press 🌐 English ⚖ 315 KB

Randomized adjuvant trial to evaluate th

Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer: 5-year results from the nishi-nippon group of the adjuvant chemoendocrine therapy for breast cancer organization

✍ Masakazu Toil; Takao Hattori; Masanobu Akagi; Kiyoshi Lnokuchi; Kunzo Orita; Kei 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 714 KB

Background. A randomized adjuvant trial was conducted from October 1982 to January 1985 to evaluate the addition of tamoxifen (TAM) to combination chemotherapy with perioperative mitomycin C (MMC) and ftorafur (FT) for patients with estrogen receptor (ER)-positive tumors and the addition of PSK, a b

Matrix Metalloproteinase-2 (MMP-2) is As

Matrix Metalloproteinase-2 (MMP-2) is Associated with the Risk for a Relapse in Postmenopausal Patients with Node-Positive Breast Carcinoma Treated with Antiestrogen Adjuvant Therapy

✍ A. Talvensaari-Mattila; P. Pääkkö; G. Blanco-Sequeiros; T. Turpeenniemi-Hujanen 📂 Article 📅 2001 🏛 Springer US 🌐 English ⚖ 58 KB